The latest analyst update on ANI Pharmaceuticals centers on a modest shift in model fair value, moving from US$110.50 to US$110.63. Bullish and bearish analysts are using this small change to reframe ...

ANI Pharmaceuticals, Inc. recently reported fourth-quarter 2025 results, with sales rising to US$247.06 million and net income reaching US$27.49 million, a sharp turnaround from a net loss a year ...

ANI Pharmaceuticals (ANIP) reported $211.37 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 53.1%. EPS of $1.80 for the same period compares to $1.02 a ...

ANI Pharmaceuticals (ANIP) reported $148.33 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.5%. EPS of $1.34 for the same period compares to $1.27 ...